The need for new vaccines.
Advances in biotechnology and immunology are yielding exciting progress in the development of new biologics and vaccines. Yet in both the developed and developing world, we see a backlog of new vaccines that are licensed but not yet used, an "innovation pile-up", which may prevent individuals and societies from benefiting from protection against preventable infectious diseases. What is the "need for new vaccines"? Reviewing the vaccines environment and the place of vaccination in public health, we present our business model that we use to sustainably deliver the benefits of vaccination and review potential solutions to accelerating the introduction and adoption of under-utilised and future vaccines.
Taylor
Kate
K
GlaxoSmithKline Biologicals, Global Vaccine Policy and Public Health Partnerships, Parc de la Noire Epine 20, B-1300 Wavre, Belgium.
Nguyen
Aurélia
A
Stéphenne
Jean
J
D035843:Biomedical Research / Q000639:trends; D005381:Financing, Organized; D006801:Humans; D018803:Models, Economic; D011634:Public Health / Q000191:economics; D014611:Vaccination / Q000706:statistics & numerical data*; D014612:Vaccines / Q000191:economics* / Q000600:supply & distribution*
D014612:Vaccines